29 patients with relapsed or progressive CLL with adverse cytogenetics (17p deletion, TP53 mutation, 11q deletion, and/or trisomy 12) and/or progression within 12 months of fludarabine treatment were included. The gene discussed is TP53; the disease is B-cell chronic lymphocytic leukemia.